XL
Xilio Therapeutics, Inc.
XLO · NASDAQ
$9.13 +0.55% (+$0.05)
1M -0.65%
Market Cap $60.0M
P/E Ratio -
Div. Yield -
ROE 50.77%
Bulios Fair Price
$9.76
6.9% upside
Current Price
$9.13
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XLO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.94x
P/B 0.83x
P/E N/A
Growth
0 /100
Declining Book val. growth 30.63%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 99.46%
Net margin 34.06%
Op. margin 48.94%
Quality
5 /100
Poor ROIC 25.82%
ROE 50.77%
ROA 14.15%
Debt
100 /100
Low Debt/Equity 0.09x
Current ratio 4.25x
Int. coverage N/A
Stability
47 /100
Moderate Beta -0.12x
EPS volatility 31.16%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XLO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Rene Russo
Employees
76
Headquarters
Waltham
Upcoming events
05 NOV
Earnings
Upcoming earnings report